Mira Pharmaceuticals, Inc. financial data

Symbol
MIRA on Nasdaq
Industry
Pharmaceutical Preparations
Location
1200 Brickell Avenue, Suite 1950 #1183, Miami, FL
State of incorporation
FL
Former names
Mira1a Therapeutics, Inc. (to 5/2/2023)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 583 %
Debt-to-equity 20.3 %
Return On Equity -337 % +22.6%
Return On Assets -281 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16.6M shares +12%
Common Stock, Shares, Outstanding 16.3M shares +10%
Common Stock, Value, Issued 1.63K USD +10.1%
Weighted Average Number of Shares Outstanding, Basic 15.1M shares +10.5%
Weighted Average Number of Shares Outstanding, Diluted 15.1M shares +10.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.83M USD +5.14%
General and Administrative Expense 5.81M USD -52.7%
Net Income (Loss) Attributable to Parent -11.2M USD -49%
Earnings Per Share, Basic -0.55 USD/shares +46.2%
Earnings Per Share, Diluted -0.55 USD/shares +46.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 4.23M USD -30.3%
Operating Lease, Right-of-Use Asset 1.27K USD
Assets 4.27M USD -52.7%
Accounts Payable, Current 636K USD
Liabilities, Current 693K USD -20.2%
Operating Lease, Liability, Noncurrent 34.5K USD
Liabilities 693K USD -23.3%
Retained Earnings (Accumulated Deficit) -26.7M USD -72.5%
Stockholders' Equity Attributable to Parent 3.57M USD -56%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 3.57M USD -56%
Liabilities and Equity 4.27M USD -52.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.05M USD +2.4%
Net Cash Provided by (Used in) Financing Activities -24.3K USD -103%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 16.3M shares +10%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.07M USD -207%
Deferred Tax Assets, Valuation Allowance 3.61M USD +102%
Deferred Tax Assets, Gross 3.62M USD +92.5%
Operating Lease, Liability 1.27K USD
Lessee, Operating Lease, Liability, to be Paid 5.09K USD
Operating Lease, Liability, Current 1.27K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 17.4K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 5.09K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 32 USD
Deferred Tax Assets, Operating Loss Carryforwards 2.43M USD +129%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Operating Lease, Payments 3.82K USD -99.3%
Additional Paid in Capital 30.3M USD +28.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.29K USD -98.6%
Interest Expense 2.6M USD -109%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%